Loading
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (6 ops.)
Latest filing published 26 Nov 2025 for ResMed Inc, €455k.
Filing timeline
BuySaleJan De Witte
Insider track record
Disclosed buys
1
Disclosed sells
6
Signal history
Closed purchases
Market purchases
1
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -19.6%Entry US$39.64 · Close at T+365 US$31.86
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Jan De Witte: trading record in brief
Jan De Witte has filed 32 times, at Integra Lifesciences Holdings Corp (17, title President & CEO) and at ResMed Inc (15, Director), between November 25, 2019 and November 26, 2025.
The record mixes both directions. A purchase of EUR 278,777, dated June 1, 2023, makes up 17% of market trades. The 5 sales, the three largest of them at ResMed Inc, total EUR 1,249,588, with a median of EUR 185,714: EUR 454,880 on November 25, 2025, EUR 431,380 on May 20, 2025 and EUR 185,714 on November 12, 2024. There are 19 grants and 7 option exercises.
The years 2023 and 2024 concentrate activity, with 10 then 11 filings, against 1 in 2019 and in 2022. Four filings fall in the last twelve months, 2 of them sales.
Brett Sandercock and Michael J. Farrell each have 5 trades within 30 days of trades by Jan De Witte, Michael J. Rider 4, all in the same direction. Filings are published a median of 2 days after the trade.
Companies and markets linked to Jan De Witte
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations32 total
2,055 shares@ US$255.0035.7% of flowReMed Common StockSEC:0000943819-25-000181:0
1,073 shares0ReMed Common StockSEC:0000943819-25-000166:0
76.45 shares@ US$250.101.3% of flowReMed Common StockSEC:0000943819-25-000115:1
487 shares@ US$250.258.3% of flowReMed Common StockSEC:0000943819-25-000115:0
2,000 shares@ US$243.4733.9% of flowReMed Common StockSEC:0001127602-25-015264:0
1,083 shares0ReMed Common StockSEC:0001127602-24-027902:0
796 shares@ US$248.8114.6% of flowReMed Common StockSEC:0001127602-24-027277:0
4,262 shares@ US$19.289.8% of flowCommon StockSEC:0000917520-24-000109:1
9,814 shares0Common StockSEC:0000917520-24-000109:0
360 shares@ US$218.295.7% of flowReMed Common StockSEC:0001127602-24-015777:0
205 shares@ US$36.220.9% of flowCommon StockSEC:0000917520-24-000037:1
205 shares0Common StockSEC:0000917520-24-000037:0
346 shares@ US$36.731.5% of flowCommon StockSEC:0000917520-24-000025:1
346 shares0Common StockSEC:0000917520-24-000025:0
597 shares@ US$42.393.0% of flowCommon StockSEC:0000917520-24-000002:1
597 shares0Common StockSEC:0000917520-24-000002:0
1,768 shares0ReMed Common StockSEC:0001127602-23-028090:0
4,262 shares@ US$36.8519.3% of flowCommon StockSEC:0001209191-23-054323:1
9,814 shares0Common StockSEC:0001209191-23-054323:0
205 shares@ US$52.871.3% of flowCommon StockSEC:0001209191-23-052775:1
205 shares0Common StockSEC:0001209191-23-052775:0
7,792 shares@ US$38.499259.2% of flowCommon StockSEC:0001209191-23-033676:0
Canonical exit: 30 Aug 2023 (T+90)
3,842 shares@ US$52.8740.8% of flowCommon StockSEC:0001209191-23-018446:0
8,848 shares0Common StockSEC:0001209191-23-009758:0
431 shares@ US$54.782.8% of flowCommon StockSEC:0001209191-23-004012:1
25 of 32 declarations
